Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

New Webcast! Research Updates from Alain Moreau, PhD

May Momentum Tuesdays

Featuring Research Updates from Alain Moreau, PhD

Welcome back to another installment of May Momentum Tuesdays, a webcast series where you will hear interviews with Directors of OMF supported Collaborative Research Centers (CRC)s. 

Today, Alain Moreau, PhD, Director of the OMF supported Collaborative Research Center at the University of Montréal, talks about a new test to discriminate Fibromyalgia from ME/CFS, insights from Long COVID research, and more.

Watch the full video on YouTube now! 

*Be sure to turn on YouTube’s closed captions to watch with subtitles!*

 

 Please consider supporting these research efforts by contributing to OMF’s May Momentum campaign today: 

More About Alain Moreau, Phd

Dr. Alain Moreau is a Full Professor in the Faculty of Dentistry (Stomatology Department), cross-appointed to the Biochemistry and Molecular Medicine Department in the Faculty of Medicine at Université de Montréal. 

 He served as Director of Research and Chief Scientific Officer of Sainte-Justine University Hospital (2013-2016). He is currently Director of The Network for Canadian Oral Health Research (NCOHR), and he serves on the Advisory Board of the Institute of Musculoskeletal Health and Arthritis of The Canadian Institutes of Health Research (CIHR).

Dr. Moreau was appointed Director of the Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis (ICanCME) Research Network, another national research network funded by CIHR. He is an internationally recognized expert on the molecular genetics of pediatric scoliosis. His discoveries led to multiple peer-reviewed papers, international conferences as a guest speaker, several awards as well as 60 patents covering innovative diagnostic tests and therapeutic molecules.

Dr. Moreau is the co-founder and Chief Scientific Officer of Inception Therapeutic Inc., a start-up based in Montreal developing diagnostic tests for primary osteoarthritis and new disease-modifying osteoarthritis drugs. Moreau’s primary research interests also target other complex adult diseases such as osteoporosis and Myalgic Encephalomyelitis.

 


 

May Momentum Tuesdays Schedule

This webcast series is a special effort to update the community on the progress underway at the OMF supported Collaborative Research Centers (CRC)s. Each Tuesday we will share a new interview with a CRC Director.

*Please note a change in the schedule: We are delighted to be sharing an interview with Ronald W. Davis, PhD, on May 31st!  

May 3, 2022 – Jonas Bergquist, MD, PhD, OMF Chief Medical Officer,
Director, Uppsala CRC. 
Video now available

May 10, 2022 – Alain Moreau, PhD, Director, Montreal CRC. Video now available.

May 17, 2022 – Christopher W. Armstrong, PhD, Director, Melbourne Collaborative

May 24, 2022 – Wenzhong Xiao, PhD, Co-Director, The Ronald G. Tompkins Harvard CRC, Director, Computational Research Center for Complex Diseases & David Systrom, MD, Co-Director, The Ronald G. Tompkins Harvard CRC

May 31, 2022 – *NEW!* Ronald W. Davis, PhD, Chair of Open Medicine Foundation Scientific Advisory Board, Director, ME/CFS Stanford Collaborative Research

Interviews will be shared on YouTube, our website, and via e-newsletter every Tuesday during #MayMomentum! Be sure to subscribe to OMF’s YouTube channel:

 

Want to take your donation to the next level?

Please consider becoming a monthly donor during May Momentum! Your monthly contribution ensures that OMF has the resources necessary to fulfill our mission to end multisystem chronic complex diseases (msCCD)

Can’t donate? No problem! There are many ways you can join in on the momentum. We invite you to find an option that works best for you:

 www.omf.ngo/maymomentum2022 

Thank you for your support.
We are so grateful to have you as part of our OMF Family! ♥

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669